|Mr. Spiro George Rombotis||Pres, CEO & Exec. Director||731.96k||N/A||1959|
|Mr. Paul McBarron||Exec. VP of Fin., CFO, COO, Sec. & Exec. Director||356.48k||N/A||1961|
|Dr. Judy H. Chiao||VP of Clinical Devel. & Regulatory Affairs||484.78k||N/A||1960|
|Prof. David Glover Ph.D., FRS FRSE||Chief Scientist||N/A||N/A||1948|
|Ms. Gill Christie||Director of HR||N/A||N/A||1957|
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.